Amisulpride in Schizophrenic Patients

Launched by SANOFI · May 30, 2006

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed as schizophrenia or schizophrenic disorder according to DSM-IV
• • Patients who need new anti-psychotic drugs or need to change the medication due to aggravations of symptoms or recurrence
• Exclusion Criteria:
• • Patients with positive symptoms in whom the disorder does not correspond to schizophrenic criteria. (e.g, schizoaffective disorder)
• • Patients hypersensitive to the active ingredient or to other ingredients of the study drug
• • Prolactin-dependant tumors, pituitary gland prolactinomas and breast cancer
• • Pheochromocytoma or Parkinson's disease
• • Pregnancy or breast feeding
• • Current or recently withdrawn from drug abuse or alcoholism
• • Chronic renal failure and other internal or surgical disease which physician decides will be worsened by trial medication or that will affect the metabolism or effects of the trial medication
• • Patients with previous histories and clinical improvement was not seen in spite of treatment with 2 anti-psychotics for over 8 weeks
• • Slow heart rate of \<55bpm, low blood potassium level, congenital prolongation of the QT interval
• • Current treatment with a drug likely to cause markedly slow heart rate(\<55bpm), low blood potassium level, slowing of intercardiac condition or prolongation of the QT interval
• • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.